HOXD13 and non-small cell lung carcinoma: A Japanese study reported that higher sPD-1 levels were associated with the improved OS in patients with NSCLC receiving anti-PD-1 immunotherapy, [67] which was consistent with another prospective study [68] and a case-control study [69].